Immunome (NASDAQ:IMNM) Price Target Raised to $38.00

Immunome (NASDAQ:IMNM) had its price target hoisted by Truist Financial from $37.00 to $38.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts have also recently weighed in on the stock. Leerink Partners decreased their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. HC Wainwright restated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Barclays started coverage on shares of Immunome in a report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective on the stock. Finally, Citigroup reiterated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Immunome has a consensus rating of “Moderate Buy” and a consensus target price of $34.64.

Immunome Stock Up 3.0%

Shares of NASDAQ:IMNM opened at $27.20 on Wednesday. The business has a 50 day moving average of $22.20 and a 200-day moving average of $22.24. The stock has a market cap of $3.09 billion, a PE ratio of -10.75 and a beta of 2.08. Immunome has a 12-month low of $8.66 and a 12-month high of $28.62.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). Equities research analysts expect that Immunome will post -2.3 earnings per share for the current year.

Insider Transactions at Immunome

In other news, Director Isaac Barchas sold 11,048 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total value of $301,058.00. Following the completion of the transaction, the director directly owned 92,211 shares in the company, valued at approximately $2,512,749.75. This represents a 10.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the sale, the insider owned 50,366 shares of the company’s stock, valued at approximately $1,263,682.94. The trade was a 64.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 682,310 shares of company stock valued at $15,675,566. Insiders own 7.21% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several hedge funds and other institutional investors have recently modified their holdings of IMNM. BlackRock Inc. bought a new position in shares of Immunome in the 2nd quarter worth about $186,588,000. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Immunome by 59.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after buying an additional 5,003,824 shares during the period. Primecap Management Co. CA bought a new position in Immunome in the second quarter valued at about $97,081,000. JPMorgan Chase & Co. increased its stake in shares of Immunome by 8,659.2% in the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after purchasing an additional 2,823,144 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in shares of Immunome in the fourth quarter worth approximately $30,710,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome News Roundup

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Investors remain focused on the FDA’s acceptance of Immunome’s varegacestat NDA and an April 2027 PDUFA decision date. The company also expects initial 2026 data from its Phase 1 IM-1021 ROR1 antibody-drug conjugate program, providing potential catalysts for the stock. Immunome catalysts and Strong Buy analysis
• Positive Sentiment: HC Wainwright maintained a Buy rating and projects a potential transition to profitability over the longer term, forecasting positive EPS of $0.40 in fiscal 2029 and $1.08 in fiscal 2030. These estimates support the longer-term investment case despite current losses.
• Neutral Sentiment: Director Isaac Barchas sold shares under a pre-arranged Rule 10b5-1 plan, including 98,712 shares from August 10–12 for roughly $2.6 million. The planned nature of the transactions makes them a less definitive signal about management’s current outlook, although the sales may weigh on sentiment. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the consensus loss of $0.51. The earnings miss triggered a recent gap lower and highlights continued cash-burn and execution risks for the clinical-stage biotechnology company. Immunome shares gap down after earnings miss
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for the near and medium term: Q3 2026 to $(0.65) from $(0.51), Q4 to $(0.68) from $(0.53), fiscal 2026 to $(2.45) from $(1.99), and fiscal 2027 to $(2.11) from $(1.72). The cuts suggest slower progress toward profitability, even though the firm retained its Buy rating.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.